首页> 外文期刊>Internal medicine journal >Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
【24h】

Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.

机译:弥散性大B细胞淋巴瘤的预后列线图结合国际预后指数和正电子发射断层扫描结果。

获取原文
获取原文并翻译 | 示例
           

摘要

Results from interim-positron emission tomography (PET) studies in diffuse large B-cell lymphoma (DLBCL) patients are varied. We evaluated the prognostic value of interim-PET in our centre. To improve concordance, interim-PET was combined with the International Prognostic Index (IPI).We retrospectively reviewed 100 new consecutive DLBCL patients treated with immunochemotherapy from 2005 to 2010. Twenty-four patients did not receive interim-PET and were excluded. Interim-PET images were re-examined using a qualitative assessment technique. Progression-free survival (PFS) and overall survival (OS) were analysed by the Cox proportional hazards model and prognostic accuracy was assessed using Harrell's C statistics (C).Eleven patients were positive, and 65 were negative at interim-PET. The 2-year OS and PFS were 70.8% and 60.0%, respectively, in the PET-negative group, 36.4% and 36.4% for the PET-positive group (log-rank P-value 0.0008 for PFS, 0.0001 for OS). The IPI and interim-PET were minimally correlated. On Cox regression analysis, both were significant indicators of PFS (P < 0.001 and P = 0.002 respectively). The prognostic accuracy for PFS of a negative PET result was limited (C = 0.63), as it was for IPI (C = 0.75), but with the two indicators combined, the predictive accuracy was improved (C = 0.81). A nomogram, predictive for relapse-free survival at 2 years, was constructed.In DLBCL patients treated with immunochemotherapy, the IPI and interim-PET provide independent prognostic information. In combination, a more powerful predictive model may be created as a nomogram. This can be refined in prospective trials and may help clinical decision making.
机译:弥漫性大B细胞淋巴瘤(DLBCL)患者的中期正电子发射断层扫描(PET)研究结果各异。我们在我们的中心评估了临时PET的预后价值。为了提高一致性,将临时PET与国际预后指数(IPI)结合使用。我们回顾性回顾了2005年至2010年接受免疫化学治疗的100例连续DLBCL新患者。有24例未接受临时PET的患者被排除在外。使用定性评估技术对中期PET图像进行重新检查。通过Cox比例风险模型分析无进展生存期(PFS)和总生存期(OS),并使用Harrell's C统计量(C)评估预后准确性。在过渡期PET中11例阳性,65例阴性。 PET阴性组的2年OS和PFS分别为70.8%和60.0%,PET阳性组为36.4%和36.4%(PFS的log-rank P值0.0008,OS的0.0001)。 IPI和临时PET的相关性最小。在Cox回归分析中,两者都是PFS的重要指标(分别为P <0.001和P = 0.002)。 PET阴性结果的PFS的预后准确性受到限制(C = 0.63),而IPI的预后准确性受到限制(C = 0.75),但结合两个指标,预测准确性得到了改善(C = 0.81)。构建了可预测2年无复发生存的诺模图。在接受免疫化学疗法治疗的DLBCL患者中,IPI和interim-PET可提供独立的预后信息。结合起来,可以将更强大的预测模型创建为列线图。这可以在前瞻性试验中加以完善,并有助于临床决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号